Jazz Pharmaceuticals reported 2025 revenue of $4.27 billion and Q1 2026 revenue of $1.07 billion. The thesis turns on whether specialty medicines, pipeline investment and portfolio execution can convert strong cash generation into durable earnings after a loss-making annual operating baseline.
References
Sources used in this report
SEC datasetSEC company tickers exchange datasetRetrieved 2026-05-20 · Issuer identity, ticker, exchange and CIK.SEC APISEC submissions APIRetrieved 2026-05-20 · Company identity, SIC, filing chronology and filing metadata.SEC XBRL APISEC companyfacts APIRetrieved 2026-05-20 · Standardized financial statement baseline.Annual reportJazz 2025 Form 10-K2026-02-24 · Annual business, risk and financial baseline.Quarterly reportJazz Q1 2026 Form 10-Q2026-05-05 · Latest interim financial baseline.Current reportJazz Form 8-K2026-05-05 · Recent filing chronology.Proxy materialJazz proxy material2025-07-14 · Governance and incentive context.